Hematology

Bristol-Myers Squibb and Celgene announce FDA clinical trial holds of PD-1 inhibitors being studied in multiple myeloma.

A patient with cancer died after treatment with a gene-edited allogeneic CAR T-cell treatment.

Leaky blood vessels in bone marrow can lead to chemotherapy failure in acute myeloid leukemia.

Top articles of the week from The American Journal of Pharmacy Benefits.

Clinical trial holds were placed on pembrolizumab to treat multiple myeloma following adverse event concerns.

Pembrolizumab (Keytruda) combination therapy may increase mortality risk among multiple myeloma patients.

High-dose vitamin C found to revert leukemia stem cells with a specific mutation back to normal cells.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

FDA to evaluate obinutuzumab (Gazyva) in combination with chemotherapy for patients with previously untreated follicular lymphoma.

A decision on the approval of obinutuzumab is expected by December 23, 2017.

Top news of the week from Specialty Pharmacy Times.

A first-in-class selective retinoic acid receptor alpha agonist is being tested in phase 2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.

T cell responses in different tumor models are fundamentally similar.

Brandon Shank, PharmD, MPH, BCOP, discusses how pharmacists work with patients undergoing chemotherapy through transitions of care.

Study finds greater rate of opioid prescribing among cancer survivors 10 or more years past their cancer diagnosis.

FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL.

Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions, discusses the expanding role of educational patient support programs in oncology.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.

Brandon Shank, PharmD, MPH, BCOP, discusses the role of the oncology pharmacist in providing consultation and maintaining communication with cancer patients during treatment.

Vyxeos is a combination chemotherapy that treats a pair of high-risk subsets of acute myeloid leukemia.

Vyxeos is indicated to treat newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

Officials with the FDA have approved enasidenib (Idhifa, Celgene Corporation) to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation, isocitrate dehydrogenase-2 (IDH2), according to a FDA press release.